Cancer Research UK, Lustgarten Foundation join SU2C in funding $12 million research to improve patient survival; HonorHealth to conduct clinical trialsContinue reading→

Announces Senior Management Changes and Appointments

Announces Stock Repurchase up to $50 MillionContinue reading→

Michael Babich Departs as Insys President and CEO

Dr. John N. Kapoor Appointed President and CEO

Daniel Brennan Appointed Executive Vice President and Chief Operating OfficerContinue reading→

Renowned biomedical engineer and former BIO5 Institute assistant director Jennifer Barton has been named interim director of the BIO5 Institute at the University of Arizona. Barton follows Dr. Fernando D. Martinez, who recently was tapped to expand the UA’s Arizona Respiratory Center.Continue reading→

Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its Naloxone Sublingual Spray for the treatment of known or suspected opioid intoxication or overdose.Continue reading→

Mentors are needed for the Student Research Program which is  part of the Scientific Enrichment Program for Students (SEPS) administered by the Neurology Research Laboratory of Barrow Neurological Institute of St. Joseph’s Hospital and Medical Center.Continue reading→

Continue reading→

Flagship Biosciences establishes a Quality Management System (QMS) for the development of medical device software to bring image analysis based Companion Diagnostics (CDx) into the clinical market. Continue reading→

International clinical trial led by TGen and HonorHealth showed significant overall survival ratesContinue reading→